Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Key facts

Sponsor

Jinsheng Hong

Principal Investigator

Jinsheng Hong

First Affiliated Hospital of Fujian Medical University

Intervention

Abbott®Ensure(dietary_supplement)

Enrollment

236 enrolled

Eligibility

18-70 years · All sexes

Timeline

2021 – 2025

Study locations (13)

• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
• Fujian Cancer Hospital, Fuzhou, Fujian, China
• 900th hospital of the joint logistics team, PLA, Fuzhou, Fujian, China
• The Nanping First Affiliated Hospital of Fujian Medical University, Nanping, Fujian, China
• Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China
• The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
• Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China
• Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Hunan Cancer Hospital, Changsha, Hunan, China
• Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, China

Collaborators

Fujian Cancer Hospital · The Second Affiliated Hospital of Fujian Medical University · The Nanping First Affiliated Hospital of Fujian Medical University · Quanzhou First Hospital · Fujian Medical University Union Hospital · Zhangzhou Affiliated Hospital of Fujian Medical University · Hunan Cancer Hospital · Jiangxi Provincial Cancer Hospital · 900 Hospital of Joint Logistics Support Force of PLA · Nanfang Hospital, Southern Medical University · The First Affiliated Hospital of Xiamen University · Zhongshan Hospital Xiamen University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06980038
  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
  National Cancer Institute (NCI)
• RECRUITINGPHASE1NCT07584499
  Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
  Sun Yat-sen University
• RECRUITINGPHASE2NCT07362979
  Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
  Sun Yat-sen University
• RECRUITINGPHASE3NCT07459296
  Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
  First Affiliated Hospital of Guangxi Medical University
• RECRUITINGNANCT06796270
  Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
  The Second Affiliated Hospital of Hainan Medical University
• RECRUITINGPHASE2NCT06059261
  Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
  Chongqing University Cancer Hospital
• RECRUITINGNCT07376603
  IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
  Qiaojuan Guo
• RECRUITINGPHASE3NCT07340515
  Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
  Man Hu

See all trials for Nasopharyngeal carcinoma →